Dual GIP/GLP-1 receptor agonist with superior weight reduction outcomes vs semaglutide alone.
A GLP-1 analogue modified with a fatty-acid chain that binds albumin, extending its half-life to roughly 13 hours. Shorter-acting than semaglutide or liraglutide, so it is dosed daily rather than weekly.
Active ingredient in Mounjaro and Zepbound. SURMOUNT-1 trial showed ~22% average body weight loss — significantly higher than semaglutide's ~15%.
The GIP component may contribute to improved tolerability, with some researchers reporting fewer GI side effects than pure GLP-1 agonists. GIP receptors are also expressed in bone and may have additional metabolic effects.